Vinehealth Digital Secures £ 4.16m Seed Follow-on Investment Led by Talis Capital – UK Tech Investment News

Vinehealth Raises $ 5.5 Million to Improve Quality of Life and Survival for Cancer Patients

The round was led by Talis Capital and was attended by play fair capital, ascension and health care tycoons.

December 3, 2021, London: today, Vinehealth Announced that it has raised $ 5.5 million in seed funding.The round was guided by Talis Capital, With the participation of former investors Play Fair Capital When rise.. Many angels also participated, including Keith Gibbs, former CEO of AXAPPP Healthcare. Newhealth partner Pam Garside; VOYAGERS Health-Tech Fund, led by WIRED founding editor David Rowan; healthcare entrepreneur and PI Capital founder David Giampaolo. Deepali Nangia, a venture partner of Speedinvest and Atomico Angel. Faisalmehumd, Vice President and Former Medical Director of Bristol Myers Squibb.When KHP, King’s College London, King’s College Hospital NHS Foundation Trust, Guys and St. Thomas NHS Trust collaboration. The company will use this money to further develop its products, expand its team and expand its business in the United States.

Founded in 2018 by Rayna Patel and Georgia Kirby, Vinehealth is a digital health platform that improves the quality of life and outcomes of cancer patients. Using a combination of behavioral science and AI, the company’s intelligent digital technology provides a highly scalable patient support program and collects a wealth of data. The Vinehealth app allows patients to better self-manage their medications, side effects and symptoms, and regularly enter “Patient Report Results” (PRO) data to support clinical decision making and services. You can inform the offer and promote clinical research. This data is of great value to pharmaceutical companies, insurance companies and hospitals. It is also clear that Vinehealth has already secured its position as a preferred supplier to the top 10 pharmaceutical companies and CROs around the world, including: Novartis.. Uniquely, Vinehealth feeds this PRO data into machine learning algorithms to promote more personalized support for patients and further improve patient outcomes.

Cancer self-management is increasingly recognized as important for improving outcomes and reducing health care costs. Without scalable PRO data, pharmaceutical companies cannot differentiate or fully realize the value of their medicines. Drugs usually fail or are delayed as a result of poor compliance and less patient involvement. Therefore, scalable patient support and a wealth of PRO data are needed to drive effective research and initiate strategies for (often highly toxic) oncology drug products. Without sufficient PRO data or patient involvement, pharmaceutical companies could significantly delay drug launches and lose $ 18 to $ 240 million in revenue each month when drugs are delayed. Traditional approaches to collecting PRO data (usually via postal surveys) are costly, time consuming, poor quality, and patient involvement is as low as about 30-40%. In contrast, Vinehealth ensured 100% compliance with the PRO collection in its first major study with the Royal Marsden NHS Trust. Companies with access to Vinehealth can view this data through a fully interoperable web dashboard. This dashboard can be fully customized for any project.

The Royal Marsden NHS Trust study reports an 87% improvement in patients’ quality of life. Better self-management is also associated with reduced hospitalization and reduced patient anxiety. Studies show that encouraging patients to record PRO data facilitates timely and effective patient-clinician communication, improving clinical decision-making, patient outcomes, and care satisfaction. Also shows evidence Effective tracking of PRO data by patients can improve survival by up to 20%. Vinehealth’s ability to generate rich patient understanding is growing with the expansion of datasets and can be used to inform ML-driven predictive analytics for all life sciences and providers in drug development or delivery. It is now possible to predict the effects of patients at each stage.

In particular, the Vinehealth app is rated 93% by ORCHA, the world’s largest single source of digital health compliance. This makes Vinehealth the most acclaimed cancer tool in the world. This is based on the CE Mark award, which was achieved at record speed earlier this year. An important regulatory milestone for the company. With over 15,000 downloads and extraordinary engagement seen in research trials, the Vinehealth platform urgently needs scalable technology to drive richer patient insights, optimize patient engagement, and improve treatment outcomes. It is set to expand rapidly throughout the life sciences sector.Digital

The funding follows many of the company’s existing grants, including a £ 1 million grant from Innovate UK’s Biomedical Catalyst, which Vinehealth provided products to eight NHS trusts in randomized controlled trials. .. Vinehealth is integrated into the entire cancer ecosystem in collaboration with major cancer charities such as Macmillan and Bowel Cancer UK. Valuable support content for these charities is included in the app. With this round of funding, 75% of Vinehealth’s board of directors will be represented by women.

Rayna Patel, Founder and CEO of Vinehealth, said:

“”We are pleased to receive the support of such trusted investors to continue our mission to empower and support cancer patients. It is essential to begin to understand how treatments affect patients. For pharmaceutical companies, our technology enables the ability to better understand patients, lead to better drug, better differentiation, faster licensing, and provide patients with personalized and scalable support. For patients, this means better care and improved results from cancer. We are now looking forward to applying rich data and machine learning capabilities to new predictive analytics to generate even richer insights for our life science partners. “

Beatrice Alilandy, Principal of Talis Capital, said:

“We are very pleased to partner with Rayna and Georgia. Given our unique value proposition that healthcare outcomes directly correlate with financial outcomes, we will be watching Vinehealth’s growth in the months prior to investing in the company. It has benefited both patients, hospitals and pharmaceutical companies. It is rare in the medical field where the parties often conflict with each other.

“From our first meeting, the resilience and mission-based attitudes of the founders quickly became apparent, making this opportunity very attractive. Both Rayna and Georgia are the lives of cancer patients. And with an apparently incredible willingness to improve survival, as a team, we have a unique combination of expertise, skills, and willingness to make Vinehealth successful. “

Faisal Mehmud, an angel investor, vice president of pharmaceutical doctors and former executive of Bristol Myers Squibb, said::

“A feature of the Vinehealth platform that efficiently supports accurate patient activation in an automated way. Rapidly integrates a wealth of frequent patient data. Uses AI to serve as an important patient intervention. By identifying potential clinically relevant patterns and combining industry-leading interfaces with user acceptance, we believe Vinehealth’s tools will be the benchmark for measuring other platforms in the future. “


Notes to the editor

contact address: Erie Crocker, [email protected]

Press kit:

About Vine health

Vinehealth’s platform uses behavioral science and AI to improve the quality of life of cancer patients through highly personalized patient support. With the Vinehealth mobile app, patients can track, understand, and optimize their care, support higher patient engagement, and communicate important information to the care team to improve results. With this, the platform will generate a wealth of real-world data and ML-driven insights to support healthcare delivery, drug development, and research. Vinehealth is in full compliance with GDPR requirements and matching, as well as proper secondary use of anonymized data.

About Talis Capital

Founded in 2009, Talis is a London-based venture capital firm that supports the visionary founders of Seed and Series A in the United States and Europe. Talis is in a unique position to invest on behalf of the multi-billion dollar entrepreneurial interdisciplinary community and add value to the entire entrepreneurial journey, at every stage of the company’s life cycle. We support founders who are looking at the future differently. Darktrace (LSE), Onfido, Ynsect, Garden, Luminance, iwoca, Plum Guide and are part of Talis’ portfolio of more than 55 companies. See for more information.

Digiqole ads

Vinehealth Digital Secures £ 4.16m Seed Follow-on Investment Led by Talis Capital – UK Tech Investment News

Source link Vinehealth Digital Secures £ 4.16m Seed Follow-on Investment Led by Talis Capital – UK Tech Investment News

Back to top button